Catalyst Wire Dossier Catalyst Wire Dossier

Pertuzumab + Trastuzumab (fixed-dose subcutaneous combination)

· Hoffmann-La Roche
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Pertuzumab + Trastuzumab (fixed-dose subcutaneous combination), covering 2021-04-26 to 2021-04-26. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer [Phase 2]

See pricing